A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK0594 in Patients With Alcohol Dependence
Latest Information Update: 20 May 2021
At a glance
- Drugs Serlopitant (Primary)
- Indications Alcoholism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; VYNE Therapeutics
Most Recent Events
- 24 Dec 2014 New trial record